

1 HUMAN ORIGIN BACTERIAL EXOPOLYSACCHARIDES

2

3 **Production of Exopolysaccharides by *Lactobacillus* and *Bifidobacterium* Strains from**
4 **Human Origin and Metabolic Activity of the Producing Bacteria in Milk.**

5

6 **N. Salazar***, **A. Prieto†**, **J.A. Leal†**, **B. Mayo***, **J.C. Bada-Gancedo***, **C.G. de los Reyes-**
7 **Gavilán*** and **P. Ruas-Madiedo*¹**.

8

9 * Instituto de Productos Lácteos de Asturias (IPLA-CSIC). Departamento de Microbiología y
10 Bioquímica de Productos Lácteos. Carretera de Infiesto s/n, 33300 Villaviciosa, Asturias
11 Spain

12 † Centro de Investigaciones Biológicas (CIB-CSIC). Ramiro de Maeztu 9, 28040 Madrid,
13 Spain

14

15

16 ¹Corresponding author: Instituto de Productos Lácteos de Asturias. Departamento de
17 Microbiología y Bioquímica de Productos Lácteos. Carretera de Infiesto s/n (P.O. box 85),
18 33300 Villaviciosa (Asturias), Spain

19 Phone: +34 985892131, Fax: +34 985892233, E-mail: ruas-madiedo@ipla.csic.es

20

21 **ABSTRACT**

22 This work reports the physico-chemical characterization of 21 exopolysaccharides
23 (EPS) produced by *Lactobacillus* and *Bifidobacterium* strains isolated from the human
24 intestinal microbiota, as well as the growth and metabolic activity of the EPS-producing
25 strains in milk. The strains belong to the species *Lactobacillus casei*, *Lactobacillus*
26 *rhamnosus*, *Lactobacillus plantarum*, *Lactobacillus vaginalis*, *Bifidobacterium animalis*,
27 *Bifidobacterium longum* and *Bifidobacterium pseudocatenulatum*. The molar mass
28 distribution of EPS fractions showed two peaks of different sizes, which is a feature shared
29 with some EPS from bacteria of food origin. In general, we have detected an association
30 between the EPS-size distribution and the EPS-producing species, although due to the low
31 number of human bacterial EPS tested we cannot establish a conclusive correlation. The main
32 monosaccharide components of the EPS under study were glucose, galactose and rhamnose,
33 which are the same than those found in food polymers; however rhamnose and glucose ratios
34 was generally higher than galactose in our human bacterial EPS. All EPS-producing strains
35 were able to grow and acidify milk; most lactobacilli produced lactic acid as the main
36 metabolite. The ratio lactic/acetic acid in bifidobacteria was 0.7, close to the theoretical one,
37 indicating that they did not produce an excessive amount of acetic acid that could adversely
38 affect the sensory properties of fermented milks. With respect to the viscosifying ability, *L.*
39 *plantarum* H2 and *L. rhamnosus* E41 and E43R were able to increase the viscosity of stirred
40 fermented milks at a similar extent to the EPS-producing *Streptococcus thermophilus* strain
41 used as positive control. Therefore, these human EPS-producing bacteria could be used as
42 adjuncts in mixed cultures for the formulation of functional foods if probiotic characteristics
43 were demonstrated. This is the first article reporting the physico-chemical characteristics of
44 EPS isolated from human intestinal microbiota.

45

46 **Key words:** “exopolysaccharide”, “human origin”, “*Bifidobacterium*”, “*Lactobacillus*”

47

48 INTRODUCTION

49 Recently, the concept of “functional starter” has been introduced referring to
50 “cultures that posses properties which contribute to food safety and / or offer one or more
51 organoleptic, technological, nutritional, or health advantages” (Leroy and De Vuyst, 2004). In
52 this context, some exopolysaccharide (EPS)-producing lactic acid bacteria (LAB) strains
53 could cover both technological and health aspects. Their capability to improve the rheological
54 characteristics of fermented milks has been proven and, more recently, health benefits have
55 been attributed to some of these biopolymers. It is well known that the key parameters
56 determining the viscosity and texture intensifying capability of EPS are mainly their chemical
57 composition, molar mass and the structure of the repeating units (Laws and Marshall, 2001)
58 as well as their interaction with the food protein matrix (Hassan, 2008). However, there are
59 very few articles reporting the relationship between the physico-chemical characteristics of
60 EPS and their putative health promoting properties (Nagaoka et al., 1994; Kitazawa et al.,
61 1998). These studies have been conducted with polymers synthesized by food origin LAB,
62 and as far as we know no data are available about the physico-chemical characteristics of
63 polymers isolated from human origin strains. Indeed, these strains could be good candidates
64 to study the relationship between the EPS production phenotype and its putative involvement
65 in their probiotic properties. In this way, we have demonstrated that human isolated
66 *Lactobacillus* and *Bifidobacterium* strains are able to produce EPS (Ruas-Madiedo et al.,
67 2007).

68 Nowadays, fresh fermented and unfermented dairy products, such as milk, yogurt,
69 ice cream and desserts are widely employed for the delivery of probiotic strains and the
70 incorporation into cheeses is under development (Boylston et al., 2004; Grattepanche et al.,
71 2008). The viability of probiotics in fermented milks has improved in recent years but this
72 was to the detriment of the variability of strains employed in the formulation of these foods

73 (Gueimonde et al. 2004). These strains have been selected as they have been shown to survive
74 well in the fermented product but their health promoting properties have not been taken into
75 account. Thus, the exploration of both technological and probiotic properties is crucial for the
76 potential application of new strains in functional food formulations.

77 In the current work, we aimed to study the growth and metabolic activity of human
78 isolated EPS-producing strains in milk. This characterization could allow us to identify
79 potential probiotic strains with appropriate technological properties for dairy applications.
80 Indeed, in a previous work we have shown that the EPS produced by these *Bifidobacterium*
81 strains had the ability to modulate the intestinal microbiota, promoting a bifidogenic effect
82 comparable to that of the prebiotic inulin (Salazar et al., 2008). Thereby, the physico-chemical
83 characteristics of EPS synthesized by these strains have been analyzed in order to establish a
84 preliminary classification of these biopolymers based on their molar mass and
85 monosaccharide composition. This could help us in a future to correlate the intrinsic
86 characteristics of EPS with their putative health benefits.

87

88 **MATERIAL AND METHODS**

89 *Bacterial Strains and Isolation of EPS Fraction from Culture Media*

90 The human-origin strains employed in this study (Table 1) have been previously
91 screened for EPS production and they were identified by 16S rRNA gene sequencing (Ruas-
92 Madio et al., 2007). Strains were grown in MRSC broth [MRS (BioKar Diagnostics,
93 Beauvais, France) supplemented with 0.25% (wt/vol) L-cysteine (Sigma Chemical Co., St.
94 Luis, MO)] and incubated at 37°C for 24 h under anaerobic conditions as previously described
95 (Salazar et al., 2008). The strain *Streptococcus thermophilus* ST-body-1 (Chr. Hansen,
96 Horsholm, Denmark), currently employed in yoghurt manufacture, was used as an EPS-
97 producing positive control. This control strain was directly inoculated from the lyophilized

98 powder into M17 broth (Oxoid Ltd., Basingstoke, Hampshire, UK) and grown overnight at
99 37°C. This culture was employed to inoculate (2%) fresh M-17 broth which was incubated
100 during 24 h.

101 The EPS fraction of strains was isolated from the cellular biomass harvested from
102 agar-MRSC plates. In short, strains were grown on the surface of agar-MRSC for 5 days
103 under anaerobic conditions at 37°C. Cellular biomass was collected with ultrapure water and
104 mixed with 1 vol of 2 M NaOH. After gently stirring overnight at room temperature, cells
105 were removed by centrifugation and EPS from the supernatants were precipitated for 48 h at
106 4°C using 2 vol of absolute cold ethanol. After centrifugation, the EPS fraction was
107 resuspended in ultrapure water, dialyzed against ultrapure water for 3 days at 4°C in dialysis
108 tubes (Sigma) of 12 to 14 kDa molecular mass cut off and finally freeze-dried.

109 ***Molar Mass Distribution of EPS Fractions***

110 Size exclusion chromatography (SEC) was employed to determine the molar mass
111 (MM) distribution of the EPS fractions. The lyophilized fractions were resuspended (5
112 mg/mL) in 0.1 M NaNO₃, kept overnight under gently stirring, and finally centrifuged
113 (10000g, 10 min) before analysis. A HPLC chromatographic system composed of an Alliance
114 2690 module injector, a Photodiode Array PDA 996 detector, a 410 refractive index (RI)
115 detector and the Empower software (Waters, Milford, MA, USA) was used. The separation
116 (50 µL vol injection sample) was carried out in two columns placed in series, TSK-Gel G3000
117 PW_{XL} + TSK-Gel G5000 PW_{XL} protected with a TSK-Gel guard column (Supelco-Sigma).
118 The mobile phase was 0.1 M NaNO₃ and the separations took place at 40°C at a flow rate of
119 0.45 mL/min. The EPS peaks were detected with the RI detector and the presence of proteins
120 was monitored through the PDA detector set at 220 nm. Standards of dextran (Fluka-Sigma),
121 ranging from 5x10³ to 4.9x10⁶ Da, were used for quantification and MM determination. For
122 quantification, the corresponding regression equations were calculated from four different

123 concentrations of each standard ($R^2 \geq 0.98$) and for the MM determination the regression
124 equation was calculated using the elution time of seven dextran standards of different MM (
125 $R^2 = 0.99$). The peaks obtained after SEC were arbitrarily distributed amongst four molar mass
126 ranges. The percentage of each peak was calculated with respect to the total amount of peaks
127 detected in each EPS fraction ($\mu\text{g peak range} \times 100 / (\mu\text{g total peaks})$).

128 ***Monosaccharide Composition of EPS Fractions***

129 The EPS fractions were hydrolyzed with 0.15, 1.5 or 3 M trifluoroacetic acid for 1 h at
130 121°C. The products were converted into their corresponding alditol acetates and then identified
131 and quantified by gas-liquid chromatography (GLC), with inositol as the internal standard (IS).
132 The neutral sugars composition was determined in an Autosystem instrument (Perkin Elmer,
133 Norwalk, CT, USA) equipped with a flame ionization detector, using a TR-CN100 capillary
134 column (30 m x 0.25 mm, 0.2 μm film thickness) and a temperature program from 210°C (1
135 min) to 240°C (ramp rate of 15°C per min, final temperature during 7 min) employing He as gas
136 carrier. Injection was performed in the split mode (split ratio 50:1). The percentage of each
137 monosaccharide was calculated with respect to the total monosaccharide content. For amino-
138 sugars identification, sample components were analyzed by GC-MS in an Agilent 7980A-5975C
139 instrument (Agilent Technologies Inc., Palo Alto, CA, USA), using a HP-5 column (30 m x 0.25
140 mm, 0.2 μm film thickness) and a temperature program of 170 to 210°C, 1 min initial hold, 2 °C
141 per min ramp rate. Peaks were identified on the basis of the sample coincidence with relative
142 retention times of commercial standards and by their mass spectra.

143 ***Growth of EPS-producing Strains in Milk***

144 Commercial pasteurized milk (Central Lechera Asturiana, Asturias, Spain) was
145 purchased from the supermarket and was supplemented with 1% Difco™ skimmed milk
146 (Becton Dickinson, MD, USA) and 0.2% yeast extract (Biokar) giving a total solid content of
147 12.5%. This supplemented milk was pasteurized again at 90°C during 5 min. MRSC or M17

148 cultures of each strain were washed twice with sterile PBS buffer pH 7.0 and were separately
149 employed to inoculate (2%) 500 mL of pasteurized milk. The inoculated milks were incubated
150 overnight (17 ± 1 h) in a water bath at 37°C and, at the end, a sample was collected in sterile
151 conditions for bacterial counting and pH measurements. Afterwards, the fermented milks
152 were cool-down to approximately 18°C with running tap water, then they were stirred 20-
153 times up and down with a spoon and stored overnight at 4°C . Three replicated batches of
154 fermented milks were carried out for each strain.

155 For bacterial counts, serial dilutions of cultured milks were made in Ringer's solution
156 (Merck, Darmstadt, Germany) and deep-plated on agar-MRSC or agar-M17. The plates were
157 incubated at 37°C during 3 days under anaerobic conditions for *Lactobacillus* and
158 *Bifidobacterium* and under aerobic conditions for *S. thermophilus*. Counts were expressed as
159 Log cfu/g and the increase of the Log units during milk fermentation was calculated.

160

161 **Isolation of EPS from Cultured Milk and Apparent Viscosity of Stirred-Fermented** 162 **Milks**

163 The EPS fraction was isolated from milks cultured with the human origin EPS-
164 producing strains. Briefly, 40 g of cultured milk was mixed with TCA solution (12% final
165 concentration) and strongly stirred for 45 min at room temperature. Precipitated bacteria and
166 proteins were removed by centrifugation ($10000g$, 4°C , 30 min) and the pH of supernatant
167 was raised to 4.5 ± 0.5 . Finally, supernatants were intensively dialyzed and freeze-dried as
168 described in the previous paragraph. Given that the yeast extract added to milk could be a
169 source of polysaccharides (mainly gluco- and galacto-mannans), the same procedure was
170 employed to obtain the precipitated-fraction of uncultured supplemented pasteurized milk.
171 The EPS yield (mg/100 mL of whey) of each strain growing in milk was calculated after

172 subtracting the precipitated-fraction (15.0±1.5 mg/100 mL of whey) obtained from the
173 uncultured milk.

174 The apparent viscosity of stirred-fermented milks was measured using the Posthumus
175 funnel (Hellings et al., 1989). The funnel was filled with approximately 450 g of stirred-
176 fermented milk and the time (s) taken to pass the mark inside the funnel was recorded. The
177 measurements were carried out in a chamber refrigerated at 4°C.

178 ***Lactose Consumption and Organic Acids Production in Fermented Milks***

179 The same HPLC chromatographic system described before was employed to quantify
180 the lactose consumption and organic acid production in fermented milks. Samples for HPLC
181 analysis were prepared as follows: 5 g of cultured milk was mixed with 20 mL of 9 mN
182 H₂SO₄, kept at 37°C with constant shaking for 2 h and, after centrifugation (10000g, 20 min),
183 supernatants were filtered through filter paper. The sample separation was carried out in an
184 ICSep ION-300 ion-exchange column (Transgenomic, San Jose, CA, USA) using 8.5 mN
185 H₂SO₄ as mobile phase at 65°C and with a flow rate of 0.4 mL/min. Lactose was detected by
186 using the RI detector and the organic acids by using the PDA detector set at 210 nm. For
187 quantification, the regression equations ($R^2 \geq 0.99$) were calculated using different
188 concentrations of the corresponding standards purchased from Fluka-Sigma. Results were
189 expressed as mM.

190 ***Production of Volatile Compounds in Fermented Milks***

191 Volatile compounds produced by lactobacilli and bifidobacteria in fermented milks
192 were determined by means of head-space (HS) GC-MS. Samples (10 g) of fermented milk
193 were mixed with cyclohexanone (0.36 mg/mL) as IS and were placed into glass tubes sealed
194 with rubber and metallic caps. They were analyzed in a 6890N Agilent GC coupled with a HS
195 automatic injector G1888 series and with a 5975B inert MS detector (Agilent). Data was
196 collected and analyzed with the ChemStation software. Samples in the HS were kept at 50°C

197 during 30 min under stirring and then separated in a HP-Innovax column (60 m x 0.25 mm x
198 0.25 μ m film thickness, Agilent). The temperature of the injector was kept at 220°C and the
199 split ratio was 20:1. The chromatographic conditions were 35°C during 5 min, 100°C (ramp
200 ratio 5°C per min) final temperature during 10 min, 240°C (ramp ratio 8°C per min) final
201 temperature during 5 min, using He as gas carrier. The electron impact energy of the MS
202 detector was set to 70eV and data were collected within the 20 to 250 amu range (at 3.12
203 scans/s). The volatile compounds were identified by comparing their mass spectra with those
204 held in the Wiley 138 library (Agilent) and by comparing their retention times with those of
205 the corresponding standards (Fluka-Sigma). The peaks were quantified as the relative total
206 ionic count abundance with respect to the IS. The concentration (μ g/mL) of each volatile
207 compound was calculated using linear regression equations ($R^2 > 0.99$) of the corresponding
208 standards.

209

210 **RESULTS AND DISCUSSION**

211 ***Characterization of EPS Produced by Human Bifidobacterium and Lactobacillus Strains***

212 A broad MM distribution, ranging from about 10^3 to 5×10^6 Da, of the EPS fractions
213 isolated from agar-MRSC plates of *Bifidobacterium* and *Lactobacillus* strains from human
214 intestinal origin was detected. In addition, within each EPS-fraction more than one peak
215 varying in size was monitored (Table 1). Then, an arbitrary classification of MM ranges has
216 been established as follows: M1: $>10^6$ Da, M2: 10^5 - 10^6 Da, M3: 10^4 - 10^5 Da, and M4: $<10^4$
217 Da. Most EPS-fractions showed two different MM peaks and all of them included the smaller
218 peak range, in some cases being present at the highest (more than 80%) proportion. The four
219 *Lactobacillus plantarum* as well as *Lactobacillus casei* BA61 and F72 strains showed a
220 second peak within the M3 range. However, *L. casei* E51 was the only lactobacilli presenting
221 a peak (2×10^6 Da) of the highest M1, whereas in the two *Lactobacillus rhamnosus* strains and

222 the *Lactobacillus vaginalis* strain the M2 peak was detected. This data indicates a different
223 pattern of EPS-MM distribution within each *Lactobacillus* species. Similar behavior was also
224 noted for the *Bifidobacterium* species. Thus, the two *Bifidobacterium animalis* strains have
225 EPS with a second peak in the M3 range; in 3 out of 4 *Bifidobacterium. longum* strains the
226 M2 range was detected, and most *Bifidobacterium pseudocatenulatum* strains presented the M1
227 highest range. However, the scarce number of strains analyzed for each species do not allow
228 us to establish a definitive direct correlation between EPS-size distribution and the EPS-
229 producing species. As far as we are aware, there is no available data in the literature reporting
230 the MM values of EPS synthesized by lactobacilli of human origin. Mozzi and co-workers
231 (2006) collected data of EPS from several mesophilic and thermophilic *Lactobacillus* strains
232 from food origin and most showed MM values lower than 10^6 Da as it was evidenced in our
233 human origin EPS-strains. But none of the food strains presented simultaneously more than
234 one MM peak. However, the EPS-fraction produced by several strains of *Lactobacillus*
235 *delbrueckii* subsp. *bulgaricus*, *S. thermophilus* and *Lactococcus lactis* subsp. *cremoris* as well
236 as that synthesized by *Lactobacillus pentosus* LPS26 presented simultaneously two EPS of
237 different MM (Grobben et al., 1997; Degeest and De Vuyst, 1999; Petry et al., 2003;
238 Vaningelgem et al., 2004; Ruas-Madiedo et al., 2005; Sánchez et al., 2006). Thus, it seems
239 that the production of two EPS peaks of different size is a relatively common characteristic
240 among LAB from food and intestinal origin. With respect to the EPS synthesized by
241 *Bifidobacterium*, scarce data is available in the literature regarding their MM distribution
242 (Nagaoka et al., 1995; Roberts, 1995; Hosono et al., 1997). The production of two EPS-
243 fractions of different sizes has been detected as well in *B. longum* and *Bifidobacterium*
244 *infantis* (Abbad-Andaloussi et al., 1995; Tone-Shimokawa et al., 1996). It has been reported
245 that the variation in the culture conditions (nitrogen and carbon sources, pH, temperature,
246 etc.) could modify the ratio of high to low MM (Degeest and De Vuyst, 1999) or might

247 induce the production of two EPS of a different chemical / structure composition (Cerning et
248 al., 1994; Petry et al., 2000; Wang & Bi, 2008). It has been also postulated that the occurrence
249 of more than one EPS fraction produced by a single strain could be due to a partial hydrolysis
250 of the highest peak as a consequence of prolonged fermentations (De Vuyst et al., 1998). We
251 can not discard a partial hydrolysis of our EPS after incubation of the producing bacteria in
252 the surface of agar-MRSC for 5 days. In fact, we were able to cultivate in MRSC broth the
253 biomass collected from solid medium after this period. However, part of the microbial
254 population could have become not viable or even dead and thus releasing glycolytic enzymes.
255 In spite of this, a relative long incubation period (5 days) has been used in our case due to the
256 generally slow growth of strains from human origin and the need for obtaining optimal
257 biomass production in order to provide enough EPS for their physico-chemical
258 characterization.

259 Regarding the chemical composition (Table 1), the monosaccharides galactose and
260 glucose were present in all polymers and rhamnose in half of them. These are also the three
261 major sugar components of EPS isolated from food environments. Mannose, fucose and N-
262 acetyl-glucosamine were detected in minor proportions in 4 out of the 11 *Bifidobacterium*
263 strains and *L. vaginalis* C32. N-acetyl-aminated sugars are also commonly found in EPS from
264 LAB, whereas fucose and mannose have been described in only a few strains (Ruas-Madiedo
265 et al., 2009). The ratio among the major monosaccharides varied depending on the strain and
266 a species-associated pattern has not been evidenced for most of them. In general for all EPS,
267 with the exception of the two *B. animalis* strains, galactose was present at a lower ratio than
268 glucose and rhamnose, when this last monosaccharide was present. On the opposite, in EPS
269 from lactobacilli of food origin galactose is often found at the same or higher proportion than
270 the other monosaccharides (Mozzi et al., 2006; Ruas-Madiedo et al., 2009). In the EPS
271 produced by our *B. animalis* and *B. longum* strains (with the exception of strain E44) from

272 human origin the monosaccharide rhamnose was present, whereas in *B. pseudocatenulatum* it
273 was absent. Even more, strains *B. longum* H73 and H67 presented a high content of rhamnose
274 as it was also detected for the EPS from most *L. casei* and *rhamnosus* strains. In this respect,
275 it is interesting to note that the polymer composition of 25 EPS produced by LAB strains from
276 food revealed that only 7 (28%) had rhamnose in their composition (Ruas-Madiedo et al.,
277 2009). Whereas, the EPS produced by our strains of human origin presented higher rhamnose
278 occurrence (11 out of 21 strains, 52%) and also higher proportion (ratio above 1). In this
279 respect, the high rhamnose content of EPS from *Bifidobacterium* has been related with their
280 capacity of protection against induced gastric ulcers in rats (Nagaoka et al., 1994). The
281 chemical characterization of the human bacterial EPS carried out in this work confirmed our
282 previous results relating the screening of genes involved in EPS synthesis (Ruas-Madiedo et
283 al., 2007) which pointed out that they were heteropolysaccharides. Finally, it is necessary to
284 be careful when using laboratory media for analyzing EPS produced by intestinal bacteria. In
285 fact, environmental conditions of laboratory and gut are drastically different and it is known
286 that culturing conditions have a major influence on the type of EPS produced. Hence
287 differences in EPS maybe expected between that found in our study and that actually
288 produced in the gut environment by the same strain.

289

290 ***Growth and Metabolic Activity of Human Origin EPS-producing Strains in Milk***

291 The EPS-producing strains isolated from human microbiota were grown in
292 pasteurized milk supplemented with 0.2% of yeast extract which was added for increasing the
293 available nitrogen source in order to allow these strains to grow in milk as single cultures. The
294 pH values and the increase of the Log cfu/g after 17±1h of incubation at 37°C are depicted in
295 Figure 1. The initial pH of milk was 6.5±0.2 and all lactobacilli were able to decrease the pH
296 below 4.5, except *L. vaginalis* C32 that only reached a value of 5.1. The pH of milks cultured

297 with *Bifidobacterium* strains presented values around 4.5, with the exception of those of *B.*
298 *longum* L55 and E44 that displayed lower values and those made with *B. animalis* C64MRa
299 and E43 which were above 5.0. Regarding the ability to grow in milk, all bacteria increased
300 their counts more than 1.5 Log cfu/g with respect to the initial levels. Among lactobacilli, *L.*
301 *casei* strains reached the highest counts followed by *L. rhamnosus* and *L. plantarum*.
302 Remarkably, several *Bifidobacterium* strains were able to increase their counts more than 2.5
303 Log units. Contrary to that expected, *B. animalis* strains showed the poorest ability to grow in
304 milk which was in accordance with their low capacity to produce organic acids.

305 Figure 2 shows the lactose consumption and organic acids production in milks
306 fermented with the EPS-producing strains from human origin. Milks cultured with *B. animalis*
307 C64MRa and E43 presented the lowest lactose consumption and consequently the lowest
308 lactic and acetic acid production, as compared with the other strains. The initial lactose
309 content in the pasteurized milk was 28.7 ± 2.4 mM and the consumption ranged between 8%
310 (for *B. animalis* E43) and 36% (for *L. plantarum* C64MRb) showing a wide variability among
311 strains. The average lactic/acetic acid ratio obtained in these fermented milks was 0.85 ± 0.14
312 for *Bifidobacterium* and 4.51 ± 1.12 for *Lactobacillus*. From a sensory point of view, the
313 production of no excessive high amounts of acetic acid as compared with the lactic acid is a
314 desirable characteristic for preserving the sensory properties of fermented milk. Ethanol was
315 produced in variable amounts depending on the strain (Table 2). Acetaldehyde and diacetyl
316 were also detected in most milks cultured with bifidobacteria. A moderate production of
317 acetic acid and a very low level of ethanol were detected in milks fermented with *L. casei*, *L.*
318 *rhamnosus* and *L. plantarum* groups with most glucose, coming from the hydrolysis of
319 lactose, being converted into lactic acid. The strain *L. vaginalis* C32 had a different behavior,
320 as it was the highest ethanol ($277 \mu\text{g/mL}$ on average) and the lowest lactic acid producer
321 among lactobacilli which is in good accordance with the heterofermentative metabolism of

322 this species (Embely et al., 1989). The ability of our strains to grow in milk is strain-
323 dependent as it was previously indicated for other probiotic *Bifidobacterium* and
324 *Lactobacillus* strains (Gilliland et al., 2002; Ostlie, et al., 2003). It is known that the milk
325 composition influences the growth capacity of the strains (Kehagias et al., 2008). This could
326 be related to the different amino acid availability among the milk types. Because in our case a
327 fast-use nitrogen source (yeast extract) was available, other factors (such as variation in β -
328 galactosidase activity, carbohydrate and peptide / amino acid transport systems, oxygen / pH
329 tolerance, etc.) behind differences in proteolytic activity could account for the different
330 capacity to grow in milk of our strains. Variations in the levels of metabolites produced
331 during milk fermentation were also detected among our strains as other authors previously
332 indicated (Baron et al., 2000; Ostlie et al., 2003). In this way, it is well known that the
333 metabolic profile of potential probiotic strains growing in milk correlates directly with the
334 sensory characteristics of the product, thereby being an important selection criterion for the
335 formulation of functional dairy foods. Finally, this study was conducted to select strains with
336 potential application for human consumption. However, since the yeast extract can not be
337 included into the formulation of fermented milks, would be the use of starters (*S.*
338 *thermophilus* and/or *L. delbrueckii* subsp. *bugaricus*) the next step in the assay of mixed
339 fermentations for application in dairy industry.

340 The apparent (Posthumus) viscosity of milks cultured with some human EPS-
341 producing strains, as well as the amount of EPS-fraction purified from the fermented milks, is
342 presented in Table 3. The amount of the EPS produced in milk by the strains under
343 characterization was low. It is worthy to mention that this value could have been
344 underestimated due to the subtraction of the precipitated fraction from the uncultured milk.
345 However, this was necessary in order to avoid the quantification of possible polysaccharides
346 coming from the small amount of yeast extract added to the milk that could be co-precipitated

347 during the EPS purification process. In general, the viscosity intensifying capability of the
348 human origin strains was very scarce and most strains showed values of apparent viscosity
349 lower than 35 s (data not shown). Only three of our lactobacilli strains conferred to the
350 fermented milks a smooth and creamy consistency comparable to that of the EPS-producing
351 *S. thermophilus* strain used as control (Table 3). These were *L. rhamnosus* E41 and E43R and
352 *L. plantarum* H2. Interestingly, the same strains were also able to increase the apparent
353 viscosity of the stirred fermented milks, although their values were lower than that of *S.*
354 *thermophilus* ST-body-1. Among these three lactobacilli, only *L. plantarum* H2 increased the
355 viscosity of the fermented milk by producing similar low EPS amount to those produced by *S.*
356 *thermophilus*, their yield being lower than that of *L. rhamnosus* E41 and E43R strains
357 although their viscosity intensifying ability was higher. Other EPS intrinsic characteristics
358 beyond the concentration reached in milk, could also account for the increase in viscosity of
359 milks fermented with the human origin EPS-producing strains (Laws and Marshall, 2001).
360 The MM of an EPS strongly influences the viscosity of fermented milks made with EPS-
361 producing strains and, in general, polymers having high MM can produce fermented milks
362 with higher viscosity (Ruas-Madiedo et al., 2009). However, in the present study we can not
363 correlate the MM values obtained in MRSC medium with the viscosity of the fermented milk
364 because, as previously stated, MM and chemical composition of EPS could greatly vary
365 depending on the culture conditions. Finally, factors such as interactions between the EPS and
366 the milk protein network (Hassan et al., 2008) or the acidification rate of the strains in milk
367 (Lucey and Singh, 1998), among others, could affect the viscosity of the stirred fermented
368 milk. However, since our human origin strains E41, E43R and H2 and the control strain
369 reached similar final pH after the same incubation period (3.82 ± 0.08 , 3.76 ± 0.02 , 3.88 ± 0.09
370 and 3.97 ± 0.06 , respectively) differences in acidification could have not account for variation
371 in the viscosity of the fermented milks.

372

373 **CONCLUSION**

374 Our EPS-producing strains from human origin presented higher rhamnose content
375 than strains of food origin previously studied by other authors. In a future this characteristic
376 could be correlated with a putative biological effect at intestinal mucosa level. Nowadays, it is
377 not possible to reproduce in the laboratory the gut conditions in order to be able to study the
378 EPS production in this environment. Thereby, the use of laboratory media is a valuable
379 technique to undertake the preliminary characterization of polymers from new origin.
380 However, given the influence of the culturing conditions on both MM and chemical
381 composition of EPS, the characterization of EPS produced in the gut environment remains as
382 a challenge for the future.

383 For dairy industry applications, it is important to know the growth capability and the
384 metabolic activity of these microorganisms in milk. Our study indicates that three EPS-
385 producing lactobacilli, *L. rhamnosus* E41, *L. rhamnosus* E43R, and mainly *L. plantarum* H2,
386 could have good technological properties. They all grew and acidified milk and, additionally,
387 they were able to increase the viscosity and to confer a desirable texture to the fermented
388 product. Most bifidobacteria were able to grow and acidify milk without producing an
389 excessive amount of acetic acid which would not be a desirable sensory characteristic in
390 fermented milks. Therefore, both lactobacilli and bifidobacteria could be used as adjuncts in
391 mixed cultures for the formulation of functional foods if they would present probiotic
392 characteristics.

393

394 **ACKNOWLEDGEMENTS**

395 This work was financed by FEDER funds (European Union) and the Spanish Plan
396 Nacional de I+D+i through projects AGL2006-03336 and AGL2007-62736. N. Salazar was

397 funded by pre-doctoral FPI-fellowship from the Spanish Ministry of Education and Science.
398 Isabel Cuesta (IPLA-CSIC) and Ana Hernández-Barranco are acknowledged for their
399 excellent technical assistance in the HPLC and GC-MS analysis. The authors are grateful to
400 Christian-Hanssen ((Hørsholm, Denmark) for kindly supply the strain *S. thermophilus* ST-
401 body-1 for research purposes.

402

403 REFERENCES

- 404 1. Abbad-Andaloussi, S., H. Talbaoui, R. Marczak, and R. Bonaly. 1995. Isolation and
405 characterization of exocellular polysaccharide produced by *Bifidobacterium longum*.
406 Appl. Microbiol. Biotechnol. 43:995-1000.
- 407 2. Baron, M., D. Roy, and J.C. Vuilleumard. 2000. Biochemical characteristics of fermented
408 milk produced by mixed-cultures of lactic starters and bifidobacteria. Lait 80:465-478.
- 409 3. Boylston, T.D., C.G. Vinderola, H.B. Ghoddusi, and J.A. Reinheimer. 2004. Incorporation
410 of bifidobacteria into cheeses: challenges and rewards. Int. Dairy J. 14:375-387.
- 411 4. Cerning, J., C.M.G.C. Renard, J.F. Thibault, C. Bouillanne, M. Landon, M. Desmazeaud,
412 and L. Topisirovic. 1994. Carbon source requirements for exopolysaccharide production
413 by *Lactobacillus casei* CG11 and partial structure analysis of the polymer. Appl. Environ.
414 Microbiol. 60:3914-3919.
- 415 5. Degeest, B., and L. De Vuyst. 1999. Indication that the nitrogen source influences both
416 amount and size of exopolysaccharides produced by *Streptococcus thermophilus* LY03
417 and modelling of the bacterial growth and exopolysaccharide production in a complex
418 medium. Appl. Environ. Microbiol. 65:2863-2870.
- 419 6. De Vuyst, L., F. Vanderveken, S. van de Ven, and B. Degeest. 1998. Production by and
420 isolation of exopolysaccharides from *Streptococcus thermophilus* grown in a milk

- 421 medium and evidence of their growth-associated biosynthesis. *J. Appl. Microbiol.* 84:
422 1059-1068.
- 423 **7.** Embely, T.M., N. Faquir, W. Bossart, and M.D. Collins. 1989. *Lactobacillus vaginalis* sp.
424 nov. from the human vagina. *Int. J. Syst. Bacteriol.* 39:368-370.
- 425 **8.** Gilliland, S.E., S.S. Reully, G.B. Kim, and H.S. Kim. 2002. Viability during storage of
426 selected probiotic lactobacilli and bifidobacteria in a yogurt-like product. *J. Food Sci.*
427 67:3091-3095.
- 428 **9.** Grattepanche, F., S. Miescher-Schwenninger, L. Meile, and C. Lacroix. 2008. Recent
429 developments in cheese cultures with protective and probiotic functionalities. *Dairy Sci.*
430 *Technol.* 88:421-444.
- 431 **10.** Grobben, G.J., W.H.M. van Casteren, H.A. Schols, A. Oosterveld, G. Sala, M.R. Smith, J.
432 Sikkema, and J.A.M. de Bont. 1997. Analysis of the exopolysaccharides produced by
433 *Lactobacillus delbrueckii* subsp. *bulgaricus* NCFB2772 grown in continuous culture on
434 glucose or fructose. *Appl. Microbiol. Biotechnol.* 48:516-521.
- 435 **11.** Gueimonde, M., S. Delgado, B. Mayo, P. Ruas-Madiedo, A. Margolles, and C.G. de los
436 Reyes-Gavilán. 2004. Viability and diversity of probiotic *Lactobacillus* and
437 *Bifidobacterium* populations included in commercial fermented milks. *Food Res. Int.*
438 37:839-850.
- 439 **12.** Hassan, A.N. 2008. *ADSA Foundation Scholar Award*: Possibilities and challenges of
440 exopolysaccharide-producing lactic cultures in dairy foods. *J. Dairy Sci.* 91:1282-1298.
- 441 **13.** Hellinga, C., D.J. Somesen, and J.P.J.M. Koenraads. 1989. Viscosity of stirred yoghurt:
442 modern techniques useful in analysing and improving routine measurements. *Neth. Milk*
443 *Dairy J.* 40:217-240.
- 444 **14.** Hosono, A., J. Lee, A. Ametani, M. Natsume, M. Hirayama, T. Adachi, and S.
445 Kaminogawa. 1997. Characterization of a water-soluble polysaccharide fraction with

- 446 immunopotentiating activity from *Bifidobacterium adolescentis* M101-4. *Biosci.*
447 *Biotechnol. Biochem.* 61:312-316.
- 448 **15.** Kehagias, C., J. Csapó, S. Konteles, E. Kolokitha, S. Koulouris, and Z. Csapó-Kiss. 2008.
449 Support of growth and formation of D-amino acids by *Bifidobacterium longum* in cows',
450 ewes', goats' milk and modified whey powder products. *Int. Dairy J.* 18:396-402.
- 451 **16.** Kitazawa, H., T. Harata, J. Uemura, T. Saito, T. Kanebo, and T. Ithoh. 1998. Phosphate
452 group requirement for mitogenic activation of lymphocytes by an extracellular
453 phosphopolysaccharide from *Lactobacillus delbrueckii* ssp. *bulgaricus*. *Int. J. Food*
454 *Microbiol.* 40:169-175.
- 455 **17.** Laws, A.P., and V.M. Marshall. 2001. The relevance of exopolysaccharides to the
456 rheological properties in milk fermented with rropy strains of lactic acid bacteria. *Int.*
457 *Dairy J.* 11:709-721.
- 458 **18.** Leroy, F., and L. De Vuyst. 2004. Lactic acid bacteria as functional starter cultures for the
459 food fermentation industry. *Trends Food Sci. Technol.* 15:67-78.
- 460 **19.** Lucey, J.A., and H. Singh. 1998. Formation and physical properties of acid milk gels: a
461 review. *Food Res. Int.* 30:529-542.
- 462 **20.** Mozzi, F., F. Vaningelgem, E.M. Hébert, R. van der Meulen, M.R. Foulquié-Moreno, G.
463 Font de Valdez, and L. De Vuyst. 2006. Diversity of heteropolysaccharide-producing
464 lactic acid bacterium strains and their biopolymers. *Appl. Environ. Microbiol.* 72:4431-
465 4435.
- 466 **21.** Nagaoka, M., S. Hashimoto, T. Watanabe, T. Yokokura, and Y. Mori. 1994. Anti-ulcer
467 effects of lactic acid bacteria and their cell wall polysaccharides. *Biol. Pharm. Bull.*
468 17:1012-1017.

- 469 **22.** Nagaoka, M., H. Shibata, I. Kimura, S. Hashimoto, K. Kimura, H. Sawada, and T.
470 Yokokura. 1995. Structural studies on a cell wall polysaccharide from *Bifidobacterium*
471 *longum* YIT4028. *Carbohydr. Res.* 274: 245-249.
- 472 **23.** Ostlie, H.M., M.H. Helland, and J.A. Narvhus. 2003. Growth and metabolism of selected
473 strains of probiotic bacteria in milk. *Int. J. Food Microbiol.* 87:17-27.
- 474 **24.** Petry, S., S. Furlan, M.A. Crepeau, J. Cerning, and M. Desmazeaud. 2000. Factors
475 affecting the exocellular polysaccharide production by *Lactobacillus delbrueckii* subsp.
476 *bulgaricus* grown in a chemically defined medium. *Appl. Environ. Microbiol.* 66:3427-
477 3431.
- 478 **25.** Petry, S., S. Furlan, E. Waghorne, L. Saulnier, J. Cerning, and E. Maguin. 2003.
479 Comparison of the thickening properties of four *Lactobacillus delbrueckii* subsp.
480 *bulgaricus* strains and physicochemical characterization of their exopolysaccharides.
481 *FEMS Microbiol. Lett.* 221:285-291.
- 482 **26.** Roberts, C.M., W.F. Fett, S.F. Osman, C. Wijey, J.V. O'Connor, and D.G. Hoover. 1995.
483 Exopolysaccharides production by *Bifidobacterium longum* BB-79. *J. Appl. Bacteriol.*
484 78:463-468.
- 485 **27.** Ruas-Madiedo, P., A. Alting, and P. Zoon. 2005. Effect of exopolysaccharides and
486 proteolytic activity of *Lactococcus lactis* subsp. *cremoris* strains on the viscosity and
487 structure of fermented milks. *Int. Dairy J.* 15:155-164.
- 488 **28.** Ruas-Madiedo, P., J.A. Moreno, N. Salazar, S. Delgado, B. Mayo, A. Margolles, and C.G.
489 de los Reyes-Gavilán. 2007. Screening of exopolysaccharide-producing *Lactobacillus* and
490 *Bifidobacterium* strains isolated from the human intestinal microbiota. *Appl. Environ.*
491 *Microbiol.* 73:4385-4388.
- 492 **29.** Ruas-Madiedo, P., N. Salazar, and C.G. de los Reyes-Gavilán. 2009. Biosynthesis and
493 chemical composition of exopolysaccharides produced y lactic acid bacteria. Pages (in

- 494 press, ISBN 978-1-904455-45-5) in *Bacterial polysaccharides: current innovations and*
495 *future*. M. Ullrich, ed. Horizon Scientific Press, Norwich, UK.
- 496 **30.** Salazar, N., M. Gueimonde, A.M. Hernández-Barranco, P. Ruas-Madiedo, and C.G. de
497 los Reyes-Gavilán. 2008. Exopolysaccharides produced by intestinal *Bifidobacterium*
498 strains act as fermentable substrates for human intestinal bacteria. *Appl. Environ.*
499 *Microbiol.* 74:4737-4745.
- 500 **31.** Sánchez, I., B. Martínez, R. Guillén, R. Jiménez-Díaz, and A. Rodríguez. 2006. Culture
501 conditions determine the balance between two different exopolysaccharides produced by
502 *Lactobacillus pentosus* LPS26. *Appl. Environ. Microbiol.* 72:7495-7502.
- 503 **32.** Tone-Shimokawa, Y., T. Toida, and T. Kawashima. 1996. Isolation and structural analysis
504 of polysaccharide containing galactofuranose from the cell walls of *Bifidobacterium*
505 *infantis*. *J. Bacteriol.* 178:317-320.
- 506 **33.** Vaningelgem, F., M. Zamfir, F. Mozzi, T. Adriany, M. Vancanneyt, J. Swings, and L. De
507 Vuyst. 2004. Biodiversity of exopolysaccharides produced by *Streptococcus thermophilus*
508 strains is reflected in their production and their molecular functional characteristics. *Appl.*
509 *Environ. Microbiol.* 70:900-912.
- 510 **34.** Wang, M., and J. Bi. 2008. Modification of characteristics of kefiran by changing the
511 carbon source of *Lactobacillus kefiranofaciens*. *J. Sci. Food Agric.* 88:763-769.

512 **Table 1:** *Bifidobacterium* and *Lactobacillus* strains of human origin and physico-chemical characteristics of their EPS fractions isolated from the
 513 cell biomass harvested from the surface of agar-MRSC plates.

Species	Strain	EPS-fractions							
		Molar mass (Da) distribution (%) ¹				Monosaccharide Ratio ²			Presence ³
		> 10 ⁶	10 ⁵ -10 ⁶	10 ⁴ -10 ⁵	< 10 ⁴	Ram	Gal	Glc	Other
<i>B. animalis</i>	C64MRa	-	-	9	91	1	1.5	2.5	-
	E43	-	-	12.3	87.7	1	2	2.5	Man
<i>B. longum</i>	H73	-	70.7	-	29.3	2	1	2.5	Fuc
	L55	-	45.9	-	54.1	1	1	4	-
	H67	-	52.6	-	47.4	4	1	4	Fuc
	E44	11.1	-	-	88.9		1	1	-
<i>B. pseudocatenulatum</i>	A102	40.6	-	22.7	36.7		1	2	-
	C52	10.4	-	-	89.6		1	1	Ram
	E515	47.1	-	-	52.9		1	2	-
	E63	38.0	-	-	61.9		1	1	-
	H34	-	56.5	-	43.5		1	1.5	Fuc, NAGlc
<i>L. casei</i>	BA61	-	-	55.4	44.6	2	1	4	-
	E51	16.1	-	-	83.9		1	2	-
	F72	-	-	58.9	41.1	2	1	2.4	-
<i>L. rhamnosus</i>	E41	-	76.9	-	23.1	3	1	3	-
	E43R	-	55.9	-	44.1	4	1	2	-
<i>L. plantarum</i>	C64MRb	-	-	18.4	81.6		1	9	-
	E112	-	-	7.5	92.5		1	5	-
	G62	-	-	11.3	88.7		1	5	-
	H2	-	-	32.3	67.7		1	3	Ram
<i>L. vaginalis</i>	C32	-	68.6	-	31.4		1	2	Man, NAGlc

514 ¹Percentage calculated with respect to the total amount (µg) of peaks measured by GPC.

515 ²Ram: rhamnose, Gal: galactose, Glc: glucose.

516 ³Content lower than 10% of the total monosaccharides. Man: mannose, Fuc: fucose, NAGlc: N-acetyl-glucosamine.

517 **Table 2:** Volatile compounds produced in milks fermented with EPS-producing
 518 *Bifidobacterium* and *Lactobacillus* strains from human origin.

Species	Strain	Mean \pm SD ($\mu\text{g}/\text{mL}$)		
		Acetaldehyde ¹	Diacetyl	Ethanol
Uncultured milk	-	0.27 \pm 0.06	0.19 \pm 0.01	2.17 \pm 0.04
<i>B. animalis</i>	C64MRa	21.86 \pm 1.24	0.99 \pm 0.16	47.91 \pm 5.81
	E43	ND	2.00 \pm 0.58	167.25 \pm 46.39
<i>B. longum</i>	H73	6.20 \pm 0.83	3.34 \pm 0.57	40.50 \pm 3.76
	L55	10.04 \pm 1.54	1.75 \pm 0.20	43.00 \pm 3.61
	H67	14.70 \pm 0.72	4.35 \pm 0.33	51.01 \pm 1.28
	E44	7.67 \pm 0.93	1.22 \pm 0.01	37.43 \pm 4.05
<i>B. pseudocatenulatum</i>	A102	16.43 \pm 0.28	3.32 \pm 1.41	35.80 \pm 2.51
	C52	12.35 \pm 5.78	2.41 \pm 0.21	31.75 \pm 0.88
	E515	14.30 \pm 0.55	3.72 \pm 1.69	30.48 \pm 5.7
	E63	ND	3.45 \pm 0.18	25.80 \pm 5.72
	H34	11.48 \pm 5.74	5.96 \pm 3.42	30.75 \pm 12.15
<i>L. casei</i>	BA61	ND	0.08 \pm 0.01	18.37 \pm 0.43
	E51	ND	1.35 \pm 0.30	35.32 \pm 0.70
	F72	ND	0.19 \pm 0.12	9.45 \pm 1.45
<i>L. rhamnosus</i>	E41	ND	0.32 \pm 0.04	13.53 \pm 0.87
	E43R	ND	0.25 \pm 0.05	12.64 \pm 0.46
<i>L. plantarum</i>	C64MRb	ND	0.31 \pm 0.10	4.09 \pm 1.53
	E112	ND	0.54 \pm 0.34	11.59 \pm 0.19
	G62	1.62 \pm 1.02	0.44 \pm 0.18	3.28 \pm 0.39
	H2	ND	0.43 \pm 0.22	13.79 \pm 0.35
<i>L. vaginalis</i>	C32	ND	1.92 \pm 1.32	277.09 \pm 125.73
<i>S. thermophilus</i> ²	St-body-1	9.38 \pm 0.56	0.75 \pm 0.11	4.92 \pm 0.79

519 ¹ND: level under detection limit

520 ²The strain *Streptococcus thermophilus* ST-body-1 was used as EPS-producing strain
 521 control.

522

523 **Table 3:** EPS production and apparent (Posthumus) viscosity of stirred milks fermented
 524 with some EPS-producing *Lactobacillus* strains from human origin.

Species	Strain	Mean \pm SD	
		Viscosity (s)	EPS-fraction ¹ (mg/100 mL whey)
<i>L. rhamnosus</i>	E41	63.3 \pm 3.7	29.0
	E43R	69.0 \pm 7.9	51.4 \pm 11.4
<i>L. plantarum</i>	H2	72.0 \pm 24.0	18.9
<i>S. thermophilus</i> ²	St-body-1	143.3 \pm 20.8	15.5 \pm 0.2

525 ¹The values were calculated after subtracting the precipitated-fraction isolated from
 526 non-fermented milk.

527 ² *Streptococcus thermophilus* ST-body-1 was used as EPS-producing strain control with
 528 high viscosity intensifying capability.
 529

530 **FIGURE LEGENDS**

531 **Figure 1.** pH values of milks fermented with EPS-producing *Bifidobacterium* and
532 *Lactobacillus* strains from human origin and increase of the Log cfu/g after incubation
533 at 37°C during 17±1 h. The strain *Streptococcus thermophilus* ST-body-1, employed in
534 yoghurt manufacture, was used as an EPS-producing strain control.


535

536 **Figure 2.** Mean values (mM) of lactose consumption and production of lactic acid and
537 acetic acid in milks fermented with EPS-producing *Bifidobacterium* and *Lactobacillus*
538 strains from human origin at 37°C during 17±1 h. The strain *Streptococcus*
539 *thermophilus* ST-body-1, employed in yoghurt manufacture, was used as an EPS-
540 producing strain control.

541

542

pH



Increase of Log cfu/g

